Is CVS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Integrated model under one roof, with revenue (annual run-rate) at ~$400 billion; FY2026 guidance at least ~$405 billion. The bear case rests on the clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. Analysts covering it are spread from $79.00 to $148.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $79.00, -26.8% from the $107.97 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Integrated model under one roof. CVS is one of few companies that combines an insurer (Aetna), a pharmacy benefit manager (Caremark), and a retail pharmacy chain. The most optimistic analyst target on CVS is $148.00, +37.1% from the $107.97 price. That figure is only reachable if this thesis works close to its best case.

The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries a large debt balance from the Aetna deal that limits flexibility if the turnaround stalls. The most pessimistic published target is $79.00, -26.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

CVS Health runs three reporting segments.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Integrated model under one roof) stalling in the reported numbers rather than in the narrative, the risk above (the clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a cheap valuation, a ~2.5% dividend, and an Aetna turnaround that showed real progress in early 2026. The bear case is that medical costs could reaccelerate, PBM reform could compress profits, and debt is high. Both can be true at once.

CVS Health is an integrated healthcare company with three parts: Aetna, a health insurer covering roughly 26 million medical members; Caremark, a pharmacy benefit manager that negotiates drug prices for plans and employers; and CVS retail pharmacies that fill prescriptions and sell front-of-store goods. Combined revenue runs around $400 billion a year.

CVS pays a quarterly dividend of about $0.665 per share, or roughly $2.66 per year. At a share price near $104, that works out to a yield of about 2.5%. Some sources report a slightly higher figure depending on the price and calculation method. Dividends can be changed or suspended by the board at any time.